405 (PB-038) - Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial

Autor: Kaufman, P.A., Pernas, S., Martin, M., Gil-Martin, M., Gomez Pardo, P., Sara, L.T., Manso, L., Ciruelos, E., Perez-Fidalgo, J.A., Hernando, C., Ademuyiwa, F.O., Weilbaecher, K., Mayer, I., Pluard, T.J., Martinez Garcia, M., Vahdat, L., Wach, A., Barker, D., Romagnoli, B., Cortes, J.
Zdroj: In European Journal of Cancer April 2018 92 Supplement 3:S117-S118
Databáze: ScienceDirect
Externí odkaz: